1. Clinical Center of the University of Sarajevo
Neuroendocrine carcinoma of the breast: A retrospective review
Faruk Skenderi, Nurija Bilalovic, Vanesa Beslagic, Edina Balta, Berisa Hasanbegovic, Semir Beslija, Semir Vranic
Clinical Center of the University of Sarajevo
3rd CONGRESS OF PATHOLOGISTS OF BOSNIA AND HERZEGOVINA 2-3 November 2016, Sarajevo, Bosnia and Herzegovina

2. INTRODUCTION
Neuroendocrine carcinoma of the breast is a rare entity (<1% of all breast carcinomas)
No data from prospective clinical trials on its optimal management
Early stage tumors are usually treated with the same strategy used for the other types of invasive breast cancer
Inno A. et al. The Oncologist 2016;21:28–32

3. INTRODUCTION
Differences between the 3rd and 4th edition of the WHO classification of the neuroendocrine breast tumors.
Jurcic P. et al. Endocrine Oncology and Metabolism 2016;21:28–32

4. Neuroendocrine breast carcioma (NEC)
Neuroendocrine architecture and cytomorphology
May have mucinous areas

5. Neuroendocrine breast carcioma (NEC)
Neuroendocrine architecture and cytomorphology

6. Neuroendocrine breast carcioma (NEC)
Neuroendocrine cytomorphology

7. Progesterone receptor
Chromogranin-A
Synaptophysin
Estrogen receptor
Progesterone receptor

8. Neuroendocrine breast carcioma (NEC)
Methods
Retrospective analysis of medical records from to 2016
Clinical, morphological and immunohistochemical characteristics evaluated

9. Neuroendocrine breast carcioma (NEC)
Clinical and pathological data
Retrospective analysis of pathological and oncological records from 2005 to 2016
2374 breast carcinomas (68/ population/year)
12 cases of NEC (0.5%)
Average age 65.3 years (range years)
Most affected age group years (33%)

10. Neuroendocrine breast carcioma (NEC)
Clinical data
2374 breast carcinomas (68/ population/year)
12 cases of NEC (0.5%)
Average age 65.3 years (range years)
Most affected age group years (33%)

11. Neuroendocrine breast carcioma (NEC)
Pathological data
Grade 2 and 3: 87%
pT2 (8/12, 67%)
pT1 (3/12, 25%)
pT4 (1/12, 8%).

12. Neuroendocrine breast carcioma (NEC)
Immunohistochemistry
Synaptophysin and chromogranin-A: 92% positive
Estrogen and progesterone receptors: 100% positive
Her-2/neu: 8% (1 case) positive

13. Neuroendocrine breast carcioma (NEC)
Outcome
Median follow-up 7 years (range, 0-10 years)
No evidence of disease 8/12 (67%)
Alive with disease 1/12 (8%)
Died of disease 3/12 (25%) in stage pT4 or disease with comorbidity in stage pT2

14. CONCLUSIONS NEC in Bosnia and Herzegovina is rare
Affects slightly older patient population than ductal breast carcinoma
Breast NEC is ER and PR positive
Breast NEC is associated with a favorable clinical course and outcome, but this is stage-dependent.

15. THANK YOU FOR YOUR ATTENTION